A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Squamous Solid Tumors
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Indini Alice
Main Facility: Oncologia Medica 1
Drug: ALE.P02
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
This is a first in human study designed to to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and preliminary anti-tumor activity of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) in monotherapy in adult patients with selected in adult patients with selected squamous solid tumors.
Last update: 21/04/2026